Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAD | Q92934 | 10/20 | 0.34 |
| ▸ | BCL2 | P10415 | 6/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.34 |
| ▸ | PMAIP1 | Q13794 | 5/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 7/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29897068 | 1.00 | BAD (0.34) | BADBCL2MCL1PMAIP1BCL2L1 | |
| SCHEMBL25246192 | 0.94 | BAD (0.37) | BADBCL2MCL1PMAIP1BCL2L1 | |
| SCHEMBL29897056 | 0.94 | BAD (0.37) | BADBCL2MCL1PMAIP1BCL2L1 | |
| SCHEMBL29897060 | 0.93 | BAD (0.36) | BADBCL2MCL1PMAIP1BCL2L1 | |
| SCHEMBL25248668 | 0.93 | BAD (0.36) | BADBCL2MCL1PMAIP1BCL2L1 | |
| SCHEMBL25256849 | 0.91 | BAD (0.34) | BADBCL2MCL1PMAIP1BCL2L1 | |
| SCHEMBL29897062 | 0.91 | BAD (0.34) | BADBCL2MCL1PMAIP1BCL2L1 | |
| SCHEMBL25286082 | 0.90 | BAD (0.36) | BADBCL2MCL1PMAIP1BCL2L1 | |
| SCHEMBL29897069 | 0.90 | BAD (0.36) | BADBCL2MCL1PMAIP1BCL2L1 | |
| SCHEMBL25289952 | 0.89 | MCL1 (0.35) | BADBCL2MCL1PMAIP1BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20220340595-A1 | MACROCYCLIC INDOLES AS MCL-1 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-10-27 | — | — | US | disclosed |
| CN-110845520-B | Macrocyclic indoles as MCL-1 inhibitors | 苏州亚盛药业有限公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-110845520-A | Macrocyclic indoles as MCL-1 inhibitors | 苏州亚盛药业有限公司 | 2020-02-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340595-A1 | MACROCYCLIC INDOLES AS MCL-1 INHIBITORS | MCL1, BCL2A1, BCL2L1 | BAD 20/4885BCL2 10/4885MCL1 1/4885 |
| US-11691989-B2 | Macrocyclic indoles as Mcl-1 inhibitors | MCL1, BCL2A1, BCL2L1 | BAD 20/4885BCL2 10/4885MCL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.